Vaccine News and Research

Latest Vaccine News and Research

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.

30 Jul 2012

Researchers describe new human tissue dendritic cell with cross-presenting function

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source - providing a new potential target for vaccines for conditions such as cancer or Hepatitis B.

30 Jul 2012

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.

30 Jul 2012

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

"The world's first vaccine against dengue fever, being developed by French drugmaker Sanofi SA, protected against three of the virus's four strains in a keenly awaited clinical trial in Thailand," the company announced on Wednesday, Reuters reports.

28 Jul 2012

AIDS roundup: Researchers examine whether the disease causes premature aging; Funding and treatment gaps; Bone marrow transplant treatments

News outlets report on scientific and political issues coming up at the International AIDS Conference being held in Washington.

27 Jul 2012

Vaccine complex delivered safely by piggybacking onto 3D DNA nanostructures

In a quest to make safer and more effective vaccines, scientists at the Biodesign Institute- at Arizona State University have turned to a promising field called DNA nanotechnology to make an entirely new class of synthetic vaccines.

27 Jul 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes.

27 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Viewpoints: 'No Cash, No Insurance, No Live'; Medicaid expansion is a good option; Eradicating polio

With all the talk about health care recently, I'm surprised that no one has challenged the crazy idea that hospitals should treat people who can't pay. This is a free market nation, dammit! The home of "No Shirt, No Shoes, No Dice" in store windows should have "No Cash, No Insurance, No Live" on our hospital doors.

26 Jul 2012

Recent release: News coverage of AIDS 2012

The NYU Development Research Institute blog features an AIDS 2012 "Conference Political Courage Meter" graphic, based on Google News hits on different search terms.

26 Jul 2012

NIDA announces 2012 recipient of Avant-Garde Award for Medications Development

Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development. Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIV infection in those receiving the vaccine.

26 Jul 2012

Recent release: Blogs discuss advancements in HIV preventative, therapeutic R&D

In this post in the Center for Global Health Policy's "Science Speaks" blog, IAVI President and CEO Margaret McGlynn, AVAC Executive Director Mitchell Warren and UNAIDS Executive Director Michel Sidibe highlight the release of a report from the HIV Vaccine & Microbicides Resource Tracking Working Group.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor.

25 Jul 2012

Little evidence exists for potential HPV type competition in cross-sectional study

Vaccines against human papillomavirus (HPV) are now recommended by the Centers for Disease Control and Prevention for both teenage boys and girls. The vaccine protects against the two most common types of the virus that cause cervical cancer: HPV 16 and 18. Is there a chance that the increased number of people vaccinated might result in an increase of other types of HPV that cause cancer?

25 Jul 2012

Bill Gates stresses importance of investment in both HIV treatment and research for vaccines, microbicides

In a symposium session on Monday at the XIX International AIDS Conference in Washington, D.C., politicians and public health experts joined Bill & Melinda Gates Foundation Co-Chair Bill Gates for a discussion about improving effectiveness and efficiency in the HIV/AIDS response, the Washington Post reports.

25 Jul 2012

Vaccine News and Research

Latest Vaccine News and Research

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

Researchers describe new human tissue dendritic cell with cross-presenting function

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

AIDS roundup: Researchers examine whether the disease causes premature aging; Funding and treatment gaps; Bone marrow transplant treatments

Vaccine complex delivered safely by piggybacking onto 3D DNA nanostructures

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

HPTN study results show additional benefits of early ART in HIV clinical outcomes

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Viewpoints: 'No Cash, No Insurance, No Live'; Medicaid expansion is a good option; Eradicating polio

Recent release: News coverage of AIDS 2012

NIDA announces 2012 recipient of Avant-Garde Award for Medications Development

Recent release: Blogs discuss advancements in HIV preventative, therapeutic R&D

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Tips to prevent illness in crowds

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

Little evidence exists for potential HPV type competition in cross-sectional study

Bill Gates stresses importance of investment in both HIV treatment and research for vaccines, microbicides

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in